OBJECTIVE: Vitamin D may promote cardiovascular health in general population and in chronic kidney disease (CKD) through inhibition of the renin-angiotensin system and anti-inflammatory effects. Although proteinuria is a marker of kidney and cardiovascular disease, few studies have examined vitamin D levels, inflammation, and proteinuria simultaneously in CKD. We evaluated the relationship between calcidiol (25D), calcitriol (1,25D), inflammation, and albuminuria in Study of Early Evaluation of Kidney Disease, a multicenter CKD cohort. DESIGN: A cross-sectional study was carried out. PARTICIPANTS: A total of 1,847 participants were studied, of which 387 were randomly selected for inflammatory biomarker assessment. PREDICTORS AND OUTCOMES: The primary predictors were 25D and 1,25D. The outcome was albuminuria (urine albumin to creatinine ratio [UACR]: >30 mg/g). RESULTS: Albuminuric patients were more likely to have decreased 25D and 1,25D levels and higher interleukin-6 (IL-6) levels compared with normoalbuminuric patients. The lowest tertiles of 25D and 1,25D were associated with 2 to 3 times increased odds of albuminuria compared with the highest tertiles when adjusted for age, gender, race, systolic blood pressure, and diabetes (OR for 25D: 3.0; 95% CI: 1.3 to 7.0; OR for 1,25D: 2.6; 95% CI: 1.7 to 3.9). In analogous linear regression models, 25D and 1,25D were significantly associated with log UACR (P < .0001, for both). In participants for whom inflammatory markers were measured, demographics-adjusted linear regression models that included IL-6 described attenuation of the relationship between 25D, 1,25D, and UACR. CONCLUSIONS: Low 25D and 1,25D levels are independently associated with albuminuria. IL-6 may be an important intermediary between vitamin D deficiency and albuminuria, or vitamin D deficiency may contribute to inflammation and subsequent albuminuria.
OBJECTIVE:Vitamin D may promote cardiovascular health in general population and in chronic kidney disease (CKD) through inhibition of the renin-angiotensin system and anti-inflammatory effects. Although proteinuria is a marker of kidney and cardiovascular disease, few studies have examined vitamin D levels, inflammation, and proteinuria simultaneously in CKD. We evaluated the relationship between calcidiol (25D), calcitriol (1,25D), inflammation, and albuminuria in Study of Early Evaluation of Kidney Disease, a multicenter CKD cohort. DESIGN: A cross-sectional study was carried out. PARTICIPANTS: A total of 1,847 participants were studied, of which 387 were randomly selected for inflammatory biomarker assessment. PREDICTORS AND OUTCOMES: The primary predictors were 25D and 1,25D. The outcome was albuminuria (urine albumin to creatinine ratio [UACR]: >30 mg/g). RESULTS: Albuminuric patients were more likely to have decreased 25D and 1,25D levels and higher interleukin-6 (IL-6) levels compared with normoalbuminuric patients. The lowest tertiles of 25D and 1,25D were associated with 2 to 3 times increased odds of albuminuria compared with the highest tertiles when adjusted for age, gender, race, systolic blood pressure, and diabetes (OR for 25D: 3.0; 95% CI: 1.3 to 7.0; OR for 1,25D: 2.6; 95% CI: 1.7 to 3.9). In analogous linear regression models, 25D and 1,25D were significantly associated with log UACR (P < .0001, for both). In participants for whom inflammatory markers were measured, demographics-adjusted linear regression models that included IL-6 described attenuation of the relationship between 25D, 1,25D, and UACR. CONCLUSIONS: Low 25D and 1,25D levels are independently associated with albuminuria. IL-6 may be an important intermediary between vitamin Ddeficiency and albuminuria, or vitamin D deficiency may contribute to inflammation and subsequent albuminuria.
Authors: Idris Guessous; William McClellan; David Kleinbaum; Viola Vaccarino; Henry Hugues; Olivier Boulat; Pedro Marques-Vidal; Fred Paccaud; Jean-Marc Theler; Jean-Michel Gaspoz; Michel Burnier; Gérard Waeber; Peter Vollenweider; Murielle Bochud Journal: Clin J Am Soc Nephrol Date: 2015-04-21 Impact factor: 8.237
Authors: Sankar D Navaneethan; Jesse D Schold; Susana Arrigain; Stacey E Jolly; Anil Jain; Martin J Schreiber; James F Simon; Titte R Srinivas; Joseph V Nally Journal: Am J Kidney Dis Date: 2011-08-04 Impact factor: 8.860
Authors: Heidi J Kalkwarf; Michelle R Denburg; C Frederic Strife; Babette S Zemel; Debbie L Foerster; Rachel J Wetzsteon; Mary B Leonard Journal: Kidney Int Date: 2011-12-28 Impact factor: 10.612
Authors: Laura H Mariani; Matthew T White; Justine Shults; Cheryl A M Anderson; Harold I Feldman; Myles Wolf; Peter P Reese; Michelle R Denburg; Raymond R Townsend; Joan C Lo; Anne R Cappola; Dean Carlow; Crystal A Gadegbeku; Susan Steigerwalt; Mary B Leonard Journal: J Ren Nutr Date: 2014-03-07 Impact factor: 3.655
Authors: Michelle M Estrella; Gregory D Kirk; Shruti H Mehta; Todd T Brown; Derek M Fine; Mohamed G Atta; Gregory M Lucas Journal: AIDS Date: 2012-01-28 Impact factor: 4.177
Authors: Jair Munoz Mendoza; Tamara Isakova; Ana C Ricardo; Huiliang Xie; Sankar D Navaneethan; Amanda H Anderson; Lydia A Bazzano; Dawei Xie; Matthias Kretzler; Lisa Nessel; L Lee Hamm; Lavinia Negrea; Mary B Leonard; Dominic Raj; Myles Wolf Journal: Clin J Am Soc Nephrol Date: 2012-05-03 Impact factor: 8.237